Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer

被引：274

作者：

Bitting, Rhonda L.

Armstrong, Andrew J. ^{[1
]}

机构：

[1] Duke Univ, Duke Canc Inst, Div Med Oncol, Durham, NC 27710 USA

来源：

关键词：

castration-resistant prostate cancer (CRPC); PI3K inhibitors; mTOR; PI3K pathway; Akt; androgen receptor signaling; combination therapy; CIRCULATING TUMOR-CELLS; PHASE-II TRIAL; MTOR COMPLEX 2; ANDROGEN RECEPTOR; RAPAMYCIN INHIBITOR; HIGH-RISK; COMBINATION THERAPY; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; MAMMALIAN TARGET;

D O I：

10.1530/ERC-12-0394

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key signaling pathway that has been linked to both tumorigenesis and resistance to therapy in prostate cancer and other solid tumors. Given the significance of the PI3K/Akt/mTOR pathway in integrating cell survival signals and the high prevalence of activating PI3K/Akt/mTOR pathway alterations in prostate cancer, inhibitors of this pathway have great potential for clinical benefit. Here, we review the role of the PI3K/Akt/mTOR pathway in prostate cancer and discuss the potential use of pathway inhibitors as single agents or in combination in the evolving treatment landscape of castration-resistant prostate cancer.

引用

页码：R83 / R99

页数：17

共 128 条

[1]

Phosphatidylinositide Dependent Kinase Deficiency Increases Anxiety and Decreases GABA and Serotonin Abundance in the Amygdala [J].

Ackermann, Teresa F. ;

Hoertnagl, Heide ;

Wolfer, David P. ;

Colacicco, Giovanni ;

Sohr, Reinhard ;

Lang, Florian ;

Hellweg, Rainer ;

Lang, Undine E. .

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2008, 22 (5-6) :735-744

[2]

Pilot study of rapamycin in patients with hormone-refractory prostate cancer [J].

Amato, Robert J. ;

Jac, Jaroslaw ;

Mohammad, Taqi ;

Saxena, Somya .

CLINICAL GENITOURINARY CANCER, 2008, 6 (02) :97-102

[3]

[Anonymous], CA CANC J CLIN, DOI DOI 10.3322/CAAC.20107

[4]

Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers [J].

Armstrong, Andrew J. ;

Marengo, Matthew S. ;

Oltean, Sebastian ;

Kemeny, Gabor ;

Bitting, Rhonda L. ;

Turnbull, James D. ;

Herold, Christina I. ;

Marcom, Paul K. ;

George, Daniel J. ;

Garcia-Blanco, Mariano A. .

MOLECULAR CANCER RESEARCH, 2011, 9 (08) :997-1007

[5]

A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer [J].

Armstrong, Andrew J. ;

Netto, George J. ;

Rudek, Michelle A. ;

Halabi, Susan ;

Wood, David P. ;

Creel, Patricia A. ;

Mundy, Kelly ;

Davis, S. Lindsay ;

Wang, Ting ;

Albadine, Roula ;

Schultz, Luciana ;

Partin, Alan W. ;

Jimeno, Antonio ;

Fedor, Helen ;

Febbo, Phillip G. ;

George, Daniel J. ;

Gurganus, Robin ;

De Marzo, Angelo M. ;

Carducci, Michael A. .

CLINICAL CANCER RESEARCH, 2010, 16 (11) :3057-3066

[6]

Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Swermenhuis, Joost F. ;

Olmos, David ;

Reid, Alison H. M. ;

Vickers, Elaine ;

A'Hern, Roger ;

Levink, Rianne ;

Coumans, Frank ;

Moreira, Joana ;

Riisnaes, Ruth ;

Oommen, Nikhil Babu ;

Hawche, George ;

Jameson, Charles ;

Thompson, Emilda ;

Sipkema, Ronald ;

Carden, Craig P. ;

Parker, Christopher ;

Dearnaley, David ;

Kaye, Stan B. ;

Cooper, Colin S. ;

Molina, Arturo ;

Cox, Michael E. ;

Terstappen, Leon W. M. M. ;

de Bono, Johann S. .

CANCER RESEARCH, 2009, 69 (07) :2912-2918

[7]

High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence [J].

Ayala, G ;

Thompson, T ;

Yang, G ;

Frolov, A ;

Li, RL ;

Scardino, P ;

Ohori, M ;

Wheeler, T ;

Harper, W .

CLINICAL CANCER RESEARCH, 2004, 10 (19) :6572-6578

[8]

Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[9]

Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression end Akt activation [J].

Bedolla, Roble ;

Prihoda, Thomas J. ;

Kreisberg, Jeffrey I. ;

Malik, Shazli N. ;

Krishnegowda, Naveen K. ;

Troyer, Dean A. ;

Ghosh, Paramita M. .

CLINICAL CANCER RESEARCH, 2007, 13 (13) :3860-3867

[10]

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors [J].

Bendell, Johanna C. ;

Rodon, Jordi ;

Burris, Howard A. ;

de Jonge, Maja ;

Verweij, Jaap ;

Birle, Diana ;

Demanse, David ;

De Buck, Stefan S. ;

Ru, Qinhua C. ;

Peters, Malte ;

Goldbrunner, Michael ;

Baselga, Jose .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) :282-290

← 1 2 3 4 5 6 7 8 9 10 →